Moein Moghimi | |
|---|---|
| Nationality | British |
| Academic background | |
| Alma mater | |
| Academic work | |
| Discipline | Biochemistry, nanotechnology |
| Sub-discipline | Drug delivery Nanomedicine Nanosafety Innate immunity and complement system Pharmaceutical nanotechnology Pharmaceutical sciences |
| Institutions | Newcastle University |
Moein Moghimi is a British professor and researcher in the fields of nanomedicine, drug delivery and biomaterials. He is currently the professor of Pharmaceutics and Nanomedicine at the School of Pharmacy and the Translational and Clinical Research Institute at Newcastle University. He is also an adjoint professor at the Skaggs School of Pharmacy, University of Colorado Denver.
He is known for his fundamental and translational research in nanomedicine and drug delivery, especially in polymeric and nanomaterials' cell and immune safety, and as an inventor of nanosystems for tissue-specific targeting.
Moghimi's publications in nanomedicine are widely cited. A study conducted by Stanford University listed Moghimi among the top 0.1% of world’s leading scientists across in all fields.[1] He founded the Centre for Pharmaceutical Nanotechnology and Nanotoxicology (CPNN) at University of Copenhagen and was its director until 2016. He co-founded S. M. Discovery Group which develops products based on his inventions.[2] He is currently editor-in-chief of the Journal of Nanotheranostics.